Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Uno studio su JNJ-90189892 per la leucemia mieloide acuta recidivante o refrattaria o le neoplasie mielodisplastiche

2 novembre 2026 aggiornato da: Janssen Research & Development, LLC

Uno studio di fase 1, primo nell'uomo, con incremento della dose di JNJ-90189892 per la leucemia mieloide acuta recidivante o refrattaria o le neoplasie mielodisplastiche

The purpose of Part 1 (Dose Escalation) of the study is to assess the effective dose (recommended Phase 2 dose[s] [RP2Ds]) that can be safely administered, and dosing regimens of JNJ-90189892 in participants with relapsed or refractory (R/R) acute myeloid leukemia (AML) or R/R higher-risk type of myelodysplastic neoplasms (MDS [type of cancer of the blood and bone marrow, which does not respond to treatment or comes back after treatment]). The purpose of Part 2 (Cohort Expansion) is to further assess the safety, tolerability and efficacy in participants with R/R AML or higher-risk types of MDS at the RP2D regimen(s). The purpose of Part 3 and 4 is to assess the effective dose (recommended Phase 2 combination dose [RP2CD]) that can be safely administered, and dosing regimens of JNJ-90189892 in combination with azacitadine (AZA) + venetoclax (VEN) in participants with R/R AML (part 3) and newly diagnosed (ND) AML (part 4).

Panoramica dello studio

Stato

Attivo, non reclutante

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Effettivo)

85

Fase

  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Concord, Australia, 2139
        • Concord Hospital
      • Melbourne, Australia, 3000
        • Peter MacCallum Cancer Centre
      • Nedlands, Australia, 6009
        • Sir Charles Gairdner Hospital
      • Marseille, Francia, 13273
        • Institut Paoli-Calmettes
      • Strasbourg, Francia, 67200
        • CHRU de Strasbourg - Hopital de Hautepierre
      • Toulouse, Francia, 31100
        • Institut Claudius Regaud
      • Madrid, Spagna, 28040
        • Hosp Univ Fund Jimenez Diaz
      • Pamplona, Spagna, 31008
        • Clinica Univ. de Navarra
      • Seville, Spagna, 41013
        • Hospital Universitario Virgen Rocio

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • A. For Parts 1, 2, and 3: Have a diagnosis, per the world health organization (WHO) 2022 criteria, of (a) Parts 1, 2, and 3: Acute myeloid leukemia (AML) or (b) Parts 1 and 2: Moderate high, high, or very high-risk myelodysplastic neoplasms (MDS) per Molecular International Prognostic Scoring System (IPSS-M); B. For Part 4 only: Previously untreated acute myeloid leukemia (AML) per the WHO 2022 criteria
  • Body weight that is greater than or equals to (>=) 40 kg
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
  • Have adequate renal function defined as Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Estimated Glomerular Filtration Rate (eGFR) >=40 milligrams per minute (mL/min) computed with the calculator on the national kidney foundation website
  • Participants must have laboratory parameters in the required range

Exclusion Criteria:

  • Has a medical history of clinically significant pulmonary compromise, particularly the current need for supplemental oxygen use to maintain adequate oxygenation
  • Has evidence of uncontrolled systemic viral, bacterial, or fungal infection. Antimicrobial prophylaxis is permitted
  • All participants- Has known allergies, hypersensitivity, or intolerance to JNJ-90189892 or its excipients; Parts 3 and 4- Has known allergies, hypersensitivity, or intolerance to venetoclax (VEN), azacitadine (AZA), or their excipients
  • Had major surgery or had significant traumatic injury within 14 days of planned first dose of JNJ-90189892
  • Had a prior or concurrent second malignancy with natural history or treatment likely to interfere with any study endpoints of safety or the efficacy of the study treatment
  • Has known active central nervous system involvement

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Non randomizzato
  • Modello interventistico: Assegnazione sequenziale
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: JNJ-90189892: Monotherapy

Participants will receive JNJ-90189892 in Part 1 (Dose escalation) of the study and the dose levels will be escalated sequentially based on the decisions of the study evaluation team (SET) until the recommended phase 2 dose (RP2D) has been identified. Participants in Part 2 (Dose expansion) will receive JNJ-90189892 at the RP2D determined in Part 1.

JNJ-90189892 will be administered.

Sperimentale: JNJ-90189892: In Combination with Azacitadine (AZA)+ Venetoclax (VEN)

Participants with relapsed or refractory (R/R) acute myeloid leukemia (AML) in Part 3 will receive JNJ-90189892+ AZA+VEN to determine the recommended Phase 2 combination dose (RP2CD). The starting JNJ-90189892 dose regimen in Part 3 will be at least 1 dose level below the highest dose level cleared in Part 1 as determined by the SET. In Part 4 participants with newly diagnosed (ND) AML will receive JNJ-90189892+ AZA+VEN starting from the JNJ-90189892 dose level determined safe in Part 3 by the SET.

JNJ-90189892 will be administered.

AZA will be administered.

VEN will be administered.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Number of Participants with Adverse events (AEs) by Severity
Lasso di tempo: From screening untill 30 days after last dose of study drug (that is approximately 2.5 years)

An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event.

From screening untill 30 days after last dose of study drug (that is approximately 2.5 years)
Part 1: Number of Participants with Dose-Limiting Toxicity (DLTs)
Lasso di tempo: At least 14 days

DLT is defined as any toxicity that requires discontinuation of treatment, any Grade 5 toxicity; Non-hematologic toxicity (Grade 3 or 4) and Hematologic toxicity.

At least 14 days

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Serum Concentration of JNJ-90189892
Lasso di tempo: Up to approximately 2.5 years

Serum samples will be analyzed to determine concentrations of JNJ-90189892.

Up to approximately 2.5 years
Area Under the Curve Over a Dosing Interval (AUC tau) of JNJ-90189892
Lasso di tempo: Up to approximately 2.5 years

AUC tau is the total observed plasma concentration of JNJ-90189892 in the body during the time between doses. AUCtau of JNJ-90189892 will be reported.

Up to approximately 2.5 years
Maximum Observed Plasma Concentration (Cmax) of JNJ-90189892
Lasso di tempo: Up to approximately 2.5 years

Cmax is the maximum observed plasma concentration of JNJ-90189892. Cmax of JNJ-90189892 will be reported.

Up to approximately 2.5 years
Minimum Observed Plasma Concentration (Cmin) of JNJ-90189892
Lasso di tempo: Up to approximately 2.5 years

Cmin is the minimum observed plasma concentration of JNJ-90189892. Cmin of JNJ-90189892 will be reported.

Up to approximately 2.5 years
Number of Participants with Presence of Anti-JNJ-90189892 Antibodies
Lasso di tempo: Up to approximately 2.5 years

Participants with presence of anti-JNJ-90189892 antibodies will be reported.

Up to approximately 2.5 years
Complete Response (CR) in Acute Myeloid Leukemia (AML)
Lasso di tempo: Up to approximately 2.5 years

CR is achieved when a participant has a best response of CR (including complete response with partial hematologic recovery [CRh] or complete response with incomplete hematologic recovery [CRi]) according to the European Leukemia Network (ENL) 2022 criteria.

Up to approximately 2.5 years
Overall Response (OR) in Myelodysplastic Neoplasms (MDS)
Lasso di tempo: Up to approximately 2.5 years

OR is achieved when a participant with MDS has a CR (any type, that is CRh or complete response with limited count recovery [CRL]), partial response (PR), or hematologic improvement (HI) according to the International Working Group (IWG) 2023 criteria.

Up to approximately 2.5 years
Complete Response in MDS
Lasso di tempo: Up to approximately 2.5 years

CR is achieved when a participant has a best response of CR (including CRh/CRL) according to the IWG 2023 criteria.

Up to approximately 2.5 years
Duration of Response (DOR)
Lasso di tempo: Up to approximately 2.5 years

DOR is defined for responsders only, as time from date of initial documentation of a response to the first documented evidence of no reponse, disease progression, relapse, initation of a new systemic anti-cancer therapy (besides hematopoietic stem cell transplant [HSCT]), or death, whichever comes first.

Up to approximately 2.5 years
Time to Response (TTR)
Lasso di tempo: Up to approximately 2.5 years

TTR is defined for responders, as the time from the first dose of study drug to first qualifying response.

Up to approximately 2.5 years
Number of Participants Achieving Transfusion Independence
Lasso di tempo: Up to approximately 2.5 years

Transfusion independence is defined as the absence of red blood cell (RBC) and platelet transfusions for 8 weeks or longer after starting study treatment for participants with AML and 16 weeks or longer for participants with MDS.

Up to approximately 2.5 years
Part 4 Only: Overall Survival (OS)
Lasso di tempo: Up to approximately 2.5 years

OS is defined as the time from the date of first dose of study treatment to the date of death due to any cause.

Up to approximately 2.5 years
Part 4 Only: Event-Free Survival (EFS)
Lasso di tempo: Up to approximately 2.5 years

EFS is defined as the time from the date of first dose of study treatment to the date of first documented evidence of treatment failure, relapse or death due to any cause, whichever occurs first.

Up to approximately 2.5 years

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Direttore dello studio: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

21 marzo 2025

Completamento primario (Stimato)

5 agosto 2027

Completamento dello studio (Stimato)

9 febbraio 2028

Date di iscrizione allo studio

Primo inviato

18 ottobre 2024

Primo inviato che soddisfa i criteri di controllo qualità

18 ottobre 2024

Primo Inserito (Effettivo)

21 ottobre 2024

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

3 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

2 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 90189892AML1001
  • 2024-514341-10-00 (Identificatore di registro: EUCT number)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

prodotto fabbricato ed esportato dagli Stati Uniti

Sì

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .